IL17A and psoriasis: Sekumab, an IL‐17 neutralizing agent, has shown efficacy in treating moderate‐to‐severe spinalarthritis and psoriasis, and has also demonstrated positive outcomes in refractory CSU patients who did not respond to omalizuma.36